** Brokerage RBC Capital Markets raises PT on drugmaker Vertex Pharmaceutical VRTX.O to $420 from $408
** Brokerage suggests VRTX's cystic fibrosis treatment, Alyftrek, could be off to a "good start"
** The FDA approved VRTX's next-generation treatment for the genetic disease that affects lungs and other organs, in December 2024, after it showed non-inferiority to Vertex's Trikafta
** RBC says declines in Trifakta prescriptions leave open a good possibility that initial conversion to Alyftrek may be faster than expected, likely outpacing Street's $79 million sales expectations for Alyftrek in Q1
** Twenty-one of 33 brokerages rate the stock "buy" or higher, 12 "hold"; their median PT is $502.23, according to the data compiled by LSEG
** As of last close, VRTX has risen 16% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。